Why Creative Medical Technology Holdings’ ADAPT interim results may mark a turning point for cell-based chronic pain treatments
Find out how positive interim ADAPT trial data for CELZ-201 may signal a turning point in regenerative, non-opioid treatment approaches for chronic lower back pain.